WHH | Women's Health Horizons - London Summit
Join 300+ senior leaders and 50+ world-renowned speakers from across the women’s health ecosystem in London on March 10, 2026.
London’s proximity to world-renowned research institutions, biotech, government, and the NHS, makes it a leader in progressive innovation.
What to expect:
A full day of keynote talks, panels, fireside chats, and workshops, including over 50 speakers
An audience of 300+ senior delegates such as FemTech founders, VCs, policymakers, and patient perspectives, to payers, providers, life science leaders, and advocacy experts
Exclusive networking opportunities with professionals from across the women's health ecosystem
Fully catered meals and refreshments
About Women's Health Horizons (WHH)
WHH is a global platform uniting changemakers to advance women’s health. We lead 1-day, high-impact summits across the globe, uniting a curated, senior audience from all corners of the women’s health ecosystem.
Focused on action and solutions, we exist to champion pioneers across investment, policy, research, FemTech founders, payers, providers and life sciences via our strategic advisory board.
London Agenda:
Welcome Keynote: How The Climate Crisis is a Women’s Health Issue
Climate change is reshaping global health outcomes, but the burden is not shared equally. This introductory keynote explores the scientific, social and economic pathways through which climate change disproportionately affects women, especially when disasters and conflicts limit access to services and health care. From heat stress to vector-borne illness, maternal and neo-natal health risks to displacement, the session highlights the urgent need to integrate gender into climate adaptation and health resilience strategies.
Ranee Thakar, Immediate Past President, Royal College of Obstetricians and Gynaecologists
Panel: Toxic Truths: Gender, Health & Environmental Pollution
Air pollution, endocrine-disrupting chemicals, microplastics, and contaminated water supplies have profound and often overlooked gender-specific impacts on women’s health. This panel explores the cumulative effects of environmental exposure on hormonal health, fertility, pregnancy outcomes, and long-term chronic disease risk. Bringing together leaders from environmental science, public health, policy, and industry, the discussion will examine where regulation and accountability fall short - and where innovation, data, and commercial solutions are emerging to better protect women’s health at scale.
Marie Morice MSc, CSC, Policy Campaigner, Women’s Environmental Network (WEN)
Panel: From Innovation to Impact: Navigating the Complexities of Medical Device Development in Women’s Health
Developing a medical device is a high-risk, capital-intensive process shaped by regulation, clinical validation, manufacturing, reimbursement, and go-to-market strategy. In women’s health, these challenges are often compounded by underfunded indications, limited clinical data, and slower adoption pathways. This session brings together founders, clinicians, regulators, and industry leaders to unpack the real-world
challenges of taking a medical device from concept to clinic, highlighting common pitfalls, regulatory considerations, and practical strategies to accelerate development without compromising safety or outcomes.
Lara Zibners MD MMEd MBA Co-Founder, Calla Lily Clinical Care
Keynote: Dr. Dudley Robinson MBBS MD FRCOG, Vice President, International Urogynecological Association (IUGA), Consultant Obstetrician and Gynaecologist, King's College Hospital
Panel: Investing in Her: Unlocking Smarter Capital Flows Across Women’s Health Innovation
Investment in women’s health remains one of the most under-leveraged opportunities in global healthcare. This panel brings together leaders from venture capital, private equity, public funding bodies, and femtech to examine how capital can be deployed more effectively across the full growth lifecycle of women’s health innovation, from menopause and fertility to cardiovascular disease, mental health, and women’s sports.
The discussion will explore why traditional investment models have struggled to deliver “hockey-stick” growth in this category and what barriers must be overcome to unlock commercial acceleration beyond Seed and Series A. The panel will also highlight the UK’s strengths in research, innovation funding, and ecosystem collaboration, and explore how coordinated investment approaches can support the long-term growth and global competitiveness of women’s health innovation through to 2030.
Malin Frithiofsson, CEO, Daya Ventures
Women’s Health Without Borders: Policy, Investment and Cross-Border Growth
Government leaders across life sciences, technology and investment from Denmark, France, the UK and Canada will explore how national strategies are enabling the international scale-up of women’s health innovation. This session will examine landmark public investments, cross-border trade and accelerator programmes, and the policy frameworks required to support FemTech companies as they expand into global markets.
The discussion will highlight where governments can learn from one another, how best-in-class ecosystems are being built, and where deeper cross-border collaboration is urgently needed to accelerate global impact in women’s health.
Fiona Thwaites, Accelerator Program Director - Women’s Health, Canadian Trade Commission
Workshop: Preventing Biased Data from Becoming Bias Care in the UK
Medical research has historically treated male bodies as the default, resulting in systemic underrepresentation of women across clinical trials, research datasets, and health AI. Despite decades of awareness and policy mandates, meaningful progress remains limited. This hands-on workshop brings together leaders from research, data, industry, and policy to examine where the gender data gap persists, why it has proven so difficult to solve, and what practical steps can be taken to design more equitable datasets, trials, and analytical frameworks. The session is focused on shared learning, practical exploration, and actionable insight within the conference setting.
Objectives:
Build a shared understanding of how current UK data practices and AI development can amplify inequities in women’s health.
Elicit and prioritise participants’ views on the UK’s readiness (data, capability,
governance, inclusion) to tackle these biases.
Collect targeted, practitioner‑informed ideas for improving practice at 1–3 critical leverage points.
Lay the groundwork for a follow‑up white paper that articulates the problem space and outlines potential solution directions - global framework for preventing biased data becoming biased care.
Facilitated by:
Helen Stewart, Consultant & Advisor, Day One North
Breakout groups + topics:
Topic 1 (Facilitator: Julia Levy, Principal, IQVIA)
Topic 2 (Dr. Elsa Zekeng, Founder & CEO, Sokerdata)
Patient Voice: Lizzy Dobres, Senior NHS Communications and Involvement Lead, previously Women’s Aid Policy lead
Panel: How the NHS and the Women’s Health Strategy Are Rewriting the Future of Care
Menopause will affect 53% of the population at some point in their lifespan - that’s 13 million women in the UK. Yet, menopause remains one of the least understood and least supported phases of women’s health within the NHS. Millions of women experience delayed diagnoses, inconsistent guidance, or symptoms dismissed entirely rooted in systemic gaps in clinical training, public health communication, and care pathways. The UK Women’s Health Strategy aims to close these gaps through better education, data-driven policy, and more equitable access to treatment.
This session uses menopause as a concrete case study of where policy intent meets (or struggles with) delivery across the system. It brings together leaders shaping that change - on how NHS structures must evolve, on delivering the Women’s Health Strategy and improving clinical confidence, and on practical, evidence-based menopause solutions that can be deployed now.
Panel: Beyond Sensitive Content: Tackling Online Censorship and Ensuring Fair Access for Women’s Health
Despite unprecedented growth in women’s health innovation, femtech brands, clinicians, and educators continue to face disproportionate online censorship. Medically accurate posts about menstruation, fertility, postpartum recovery, pelvic health, and sexual wellbeing are flagged as “adult content,” blocked from advertising, or quietly suppressed by recommendation algorithms.
This panel explores the moderation policies, AI-driven systems, and commercial incentives that shape what women are allowed to see, and say, online.
Anna O’Sullivan, Founder & Editor, FutureFemHealth, Co-Founder, CensHERship
Deirdre O’Neill, Co-Founder, Hertility
Olivia DeRamus, Founder & CEO of Communia
Panel: Leading Change: How the UK’s World-Class Universities Are Shaping the Future of Women’s Health
The UK’s leading universities play a critical role in shaping the global women’s health agenda, from foundational research and data infrastructure to policy influence and the translation of innovation into practice. This panel brings together senior academic leaders from the UK’s most prestigious institutions to examine how universities are driving progress in women’s health, where structural and systemic barriers persist, and what must change next.
The discussion will explore funding priorities, persistent data gaps, interdisciplinary collaboration, and how academic leadership can accelerate real-world impact at scale, positioning the UK as a global leader in women’s health research and innovation.
Christiane Hagel, Health Innovation, Data & AI Strategy, World Health Organization, Health Systems, Informatics & Policy Research, University of Oxford, President, Oxford FemTech, Co-Founder, FemTech Germany e.V.
Joyce Harper, Professor of Reproductive Science at UCL’s Institute for Women’s Health
Networking Cocktail Reception
Stay up-to-date on WHH
Join our community on LinkedIn
Learn more about us: https://www.whhwomenshealthhorizons.com/